OptiNose Inc (NASDAQ:OPTN) has received a consensus broker rating score of 1.33 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and two have issued a strong buy rating on the company.
Brokers have set a 1 year consensus price objective of $29.67 for the company and are anticipating that the company will post ($0.46) earnings per share for the current quarter, according to Zacks. Zacks has also assigned OptiNose an industry rank of 156 out of 265 based on the ratings given to related companies.
OPTN has been the topic of a number of research analyst reports. Royal Bank of Canada initiated coverage on OptiNose in a research report on Tuesday, November 7th. They set an “outperform” rating and a $33.00 price target on the stock. BMO Capital Markets initiated coverage on OptiNose in a research report on Tuesday, November 7th. They set an “outperform” rating and a $29.00 price target on the stock. Jefferies Group started coverage on OptiNose in a research report on Tuesday, November 7th. They set a “buy” rating and a $27.00 price target on the stock. Finally, Piper Jaffray Companies started coverage on OptiNose in a research report on Tuesday, November 7th. They issued an “overweight” rating and a $27.00 target price on the stock.
OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.